Real‐world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study
Developmental Medicine & Child Neurology · 2026-03 · 68 (3) · 407-417
DOI: 10.1111/dmcn.16482 ↗Kurz gefasst
Fachartikel in der Zeitschrift Developmental Medicine & Child Neurology, online erschienen am 11.09.2025. Verfasst von Louise Cosand und 3 weiteren Autor:innen. Beteiligte Einrichtung: Acadia Pharmaceuticals, San Diego, CA, USA. Hauptthemen laut MEDLINE: Rett Syndrome. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Acadia Pharmaceuticals, Inc., ACADIA Pharmaceuticals.
Abstract (Originalsprache)
Aim
To describe the real‐world effects of trofinetide in individuals with Rett syndrome (RTT) using the 18‐month follow‐up analysis of the LOTUS study.
Method
Caregivers of any patients who were prescribed trofinetide under routine clinical care were eligible to participate. Assessments included the Behavioral Improvement Questionnaire (BIQ), the Quality of Life Inventory‐Disability (QI‐Disability) questionnaire, the Gastrointestinal Health Questionnaire, and safety monitoring. Data are reported to 12 months since the initiation of trofinetide.
Results
Overall, 227 caregivers participated in this follow‐up. The median trofinetide dose at week 1 was 36.0% of the target dose and increased to over 80% by week 10 onwards; 55.2% of patients took the full trofinetide recommended daily dose. Caregivers (71%–90%) reported behavioral improvements across months 1 to 12 with the BIQ, including non‐verbal communication (48%–71%), alertness (44%–70%), and social interaction and connectedness (33%–58%). The median QI‐Disability total score change from baseline ranged from 4.7 to 4.6 in months 1 to 12. The incidence of diarrhea varied from weeks 1 to 12 (23%–50%) and months 4 to 12 (26%–38%); most reports of diarrhea were contained inside the patient's diaper. Safety reports were consistent with previous trofinetide clinical trials.
Interpretation
Results from the LOTUS study show improvements in the symptoms of RTT, with early insights into managing gastrointestinal symptoms in the context of real‐world patient care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Acadia Pharmaceuticals, San Diego, CA, USA.
- The Kids Research Institute Australia, The Centre for Child Health Research, University of Western Australia, Perth, WA, Australia.
- Curtin School of Allied Health, Faculty of Health Sciences, Curtin University, Perth, WA, Australia.
ORCID-Profile: Louise Cosand, Jenny Downs
Förderung
- Acadia Pharmaceuticals, Inc.
- ACADIA Pharmaceuticals
Zitieren
APA
Cosand, L., Mayman, H., Downs, J., & Abler, V. (2026). Real‐world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study. Developmental Medicine & Child Neurology, 68(3), 407-417. https://doi.org/10.1111/dmcn.16482
Vancouver
Cosand L, Mayman H, Downs J, Abler V. Real‐world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study. Developmental Medicine & Child Neurology. 2026;68(3):407-417. doi:10.1111/dmcn.16482
BibTeX
@article{Cosand2026,
author = {Cosand, Louise and Mayman, Haya and Downs, Jenny and Abler, Victor},
title = {Real‐world benefits and tolerability of trofinetide for the treatment of Rett syndrome: The LOTUS study},
journal = {Developmental Medicine & Child Neurology},
year = {2026},
volume = {68},
number = {3},
pages = {407--417},
doi = {10.1111/dmcn.16482}
}
EUVIMED